Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-CD22 CAR-T in R/R B-ALL
NCT04714593Phase 2Unknown
- Sponsor
- Shanxi Cancer Hospital
- Start
- Jan 2021
- Primary completion
- Dec 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CD19-CD22 CAR-T cells (Shanxi Province Cancer Hospital) in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Shanxi Cancer Hospital. Status: unknown.
02
Drugs
CD19-CD22 CAR-T cells (Shanxi Province Cancer Hospital)
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT04714593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04714593.